CytomX Therapeutics, Inc. (CTMX)
| Market Cap | 124.26M |
| Revenue (ttm) | 70.74M |
| Net Income (ttm) | -91.94M |
| Shares Out | 65.40M |
| EPS (ttm) | -1.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,443,867 |
| Open | 1.95 |
| Previous Close | 1.87 |
| Day's Range | 1.85 - 2.00 |
| 52-Week Range | 1.51 - 7.53 |
| Beta | 0.76 |
| Analysts | Buy |
| Price Target | 11.37 (+498.4%) |
| Earnings Date | Aug 4, 2022 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gas... [Read more...]
Financial Performance
In 2021, CTMX's revenue was $69.57 million, a decrease of -30.68% compared to the previous year's $100.36 million. Losses were -$83.61 million, 154.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is 11.37, which is an increase of 498.42% from the latest price.
News
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on J...
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean...
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic - - EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
- Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 -
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it ...
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D.
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Joh...
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Fre...
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual M...
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that pre...
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 -
CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean...
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it w...
CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced the promo...
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of A...
- CX-904 is CytomX's first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic - - CX-904 is CytomX's first T-cell-engaging bispecific antibody and the s...
CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy...
Why CytomX Therapeutics Stock Is Crashing Today
Investors didn't like the company's preliminary phase 2 results for its experimental cancer therapy.
CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate
CytomX Therapeutics Inc (NASDAQ: CTMX) announced preliminary Phase 2 results of CX-2029 in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carc...
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class An...
-Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. Enrollment continues-
Implied Volatility Surging for CytomX Therapeutic (CTMX) Stock Options
Investors need to pay close attention to CytomX Therapeutic (CTMX) stock based on the movements in the options market lately.
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy...
CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.67% and -5.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
-Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021-
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunoth...
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...